TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01366144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT02445781

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucose clamp
Description: Different levels of hypoglycemia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucose clamp
Description: Different levels of hypoglycemia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucose clamp
Description: Different levels of hypoglycemia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucose clamp
Description: Different levels of hypoglycemia
Study: NCT01948882

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESS505 (BAY1454033)
Study: NCT03549728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: In group A, at the day of oocyte retrieval, after oocytes collection, 30 mU (300 mcg/0.5 ml) of G-CSF (NeupogenTM, Filgastrim, Amgen Inc., Thousand Oaks, CA, USA) was administered by slow transcervical intrauterine infusion with IUI catheter (AINSEGREY, RIMOS, Italy). In controls, normal saline was used for intrauterine infusion instead of G-CSF.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intrauterine infusion of normal saline
Description: In group B (controls), normal saline will be used for intrauterine infusion instead of granulocyte colony-stimulating factor on the day of oocyte retrieval.
Study: NCT01063426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Atorvastatin+enoxaparin
Description: High dose atorvastatin 80mg/day for 7days after index surgery (total knee replacement arthroplasty, TKRA). At the same time Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin 40mg SQ/day 12hr before TKRA and on day 1 to day7 after TKRA should be administered.
Study: NCT00529620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfalene-pyrimethamine plus amodiaquine
Description: Monthly treatments during the malaria transmission season

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dihydroartemisinin plus piperaquine
Description: Monthly treatments during the transmission season

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfadoxine pyrimethamine plus piperaquine
Description: Monthly treatments during the malaria transmission season
Study: NCT02971683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept subcutaneous
Description: Specified dose of Abatacept subcutaneous on specified days
Study: NCT00343044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan administered days 1, 8, and 15 of each 28 day cycle. Dose was 4 mg/m2 administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: bevacizumab administered IV 10 mg/kg, days 1 and 15 of 28 day cycle.
Study: NCT02575326

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Control
Description: Teens in the control group will receive standard or usual care as provided by their physician.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: a provider administered, tailored discussion guide
Description: Teens in the intervention group will receive a provider administered, tailored discussion guide based on motivational interviewing techniques.
Study: NCT00940615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: , participants assigned to the exercise treatment group of the proposed study will participate in an aerobic exercise regimen of brisk walking on a treadmill for a 60 minute interval, three times a week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stretching/toning
Description: Individuals in the control group will participate in a low intensity stretching and toning session for 60 minutes, three times a week
Study: NCT03293992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% RO7058584
Description: Once daily morning administration for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% RO7058584
Description: Once daily morning administration for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% RO7058584
Description: Once daily morning administration for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% RO7058584
Description: Once daily morning administration for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% RO7058584
Description: Once daily morning administration for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% RO7058584
Description: Once daily morning administration for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Once daily morning administration for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Once daily morning administration for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Once daily morning administration for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Description: Once daily morning or evening dosing
Study: NCT00179660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Capsules for oral administration.
Study: NCT02912975

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mirror treatment
Description: The mirror treatment: The patient sits on a chair, both knees in 90 degrees flexion, both lower limbs undressed, and places a mirror of 100 cm x 25 cm along the trans-tibial amputation stump so that the uninjured limb is reflected in the mirror while the amputation stump can not be seen by the patient. The patient then performs slow repeated movements of the foot from neutral position into maximum flexion while closely observing the reflected image of the uninjured limb - the illusion of a limb regained - in the mirror. The procedure goes on uninterrupted for five minutes in the morning and in the evening in the home of the study patient.
Study: NCT02243553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan hydrobromide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan hydrobromide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan hydrobromide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan hydrobromide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin injection
Study: NCT01988246

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Patients will be assigned to treatment with 2 mg intravitreal Aflibercept injection (0.05 mL or 50 microliters) administered at the time of surgery (post cataract excision) or sham injection.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham injection. No actual injection. No medication is used.
Study: NCT00185185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil
Description: tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atenolol
Description: tablets
Study: NCT04385953

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care
Study: NCT00607555

Intervention type: DEVICE
Intervention: Insertion of specialized feeding tube for monitoring of EAdi
Description: The specialized feeding tube will be inserted into the esophagus and positioned at the level of the crural diaphragm. EAdi will be measured with miniaturized coated stainless steel electrodes mounted on the feeding tube. The tube is connected to a monitor where EAdi will be recorded continuously throughout the entire study period
Study: NCT03378167

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MICROBIOTA
Description: Fecal microbiota enema (RBX2660) infused via colonoscope x 1 + oral microbiota capsules (RBX7455) x 6 weeks. The fecal microbiota enema (RBX2660) prepared by Rebiotix has received Health Canada Clinical Trials Application (CTA), and U.S. Food and Drug Administration Investigational New Drug Application (IND) approval for clinical trials in patients with recurrent Clostridium difficile infection, and pediatric inflammatory bowel disease. The human-derived fecal oral microbiota capsule (RBX7455) has received U.S. Food and Drug Administration Investigational New Drug Application (IND) approval for clinical trials in patients with recurrent Clostridium difficile infection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo enema (Normal Saline) infused via colonoscope x 1 + oral placebo capsules (dextrose-containing capsules) x 6 weeks.~NOTE: Patients randomized to the control group will be given the option of receiving open-label treatment, with the intervention therapy, either: upon completion of the trial, or if they are removed from the trial due to disease exacerbation or other adverse event, at the discretion of their primary gastroenterologist.
Study: NCT01266096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET scan with 124I-cRGDY-PEG-dots
Description: Five (5) patients with newly diagnosed or recurrent melanoma, and 18 malignant brain tumor patients (surgical (n=13) or non-surgical candidates (n=5)). Patients with either primary or metastatic brain tumors, will be i.v. injected with approximately 5 mCi (3.4-6.7 nanomoles) of 124I-cRGDY-PEG-dots (specific activity range 750.0 - 1450 mCi/mol) and undergo the microdosing study for purposes of collecting pharmacokinetic and dosimetry data. All studies will be performed using a dedicated scanner, which integrates a dedicated PET scanner and a spiral CT with proprietary fusion software.
Study: NCT02971683

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of Abatacept subcutaneous
Study: NCT03521960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspirone oral capsule
Description: 15 milligrams, three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 0 milligrams (placebo), three times daily
Study: NCT04221451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venglustat GZ402671
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT01328574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105
Description: 15 mg/kg intravenously
Study: NCT03498612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT02147548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etifoxine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lorazepam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02459873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer games to assess change in executive function skills
Description: Children get access to computer games for 10 weeks for an hour each week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer games to assess change in executive function skills
Description: Children get access to computer games for 10 weeks for an hour each week.
Study: NCT01850225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auditory brainstem implant
Study: NCT03963726

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiotherapy
Description: The liver metastases were treated with Cyberknife stereotactic radiotherapy.Using multimodal image fusion to outline the target area.According to the volume, location, organ function and other factors, the dosage of radiotherapy was determined. The range of BED value of radiotherapy was 90-120 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 70-90 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: microwave alabation
Description: The colorectal cancer patients with liver metastases will receive microwave ablation.3D printing template was used to assist microwave ablation.For those whose lesions are directly smaller than 5.0cm, the ablation time is about 10 min and 15 min, and the ablation time is more than 15min in patients larger than 5.0cm.
Study: NCT02967185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy for Insomnia
Description: Treatment will consist of 4 weekly, 1 hour sessions and will be conducted by a trained graduate assistant on an individual basis. Treatment components will include education about aging and sleep. It will also include instruction in techniques designed to: (a) promote good sleep habits, (b) restrict the use of the bed and bedroom to sleep and sleep-conducive activities, (c) modify bed and wake times to better match the participants sleep needs, and (d) promote relaxation. Daily home practice of these techniques will be encouraged. Participants will maintain logs of their home practice sessions and will continue to record their daily sleep habits throughout treatment.
Study: NCT01930370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicarbonate hemodialysis solution (low concentration)
Description: One-week experimental session (3 dialysis treatments) with low dialysate bicarbonate (28 mmol/L)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicarbonate hemodialysis solution (high concentration)
Description: One-week experimental session with high dialysate bicarbonate (38 mmol/L)
Study: NCT01002326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Description: 20 sessions of Cognitive-Behavioral Therapy
Study: NCT03664830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Up to two subcutaneous injections of plerixafor (starting dose level: 240 µg/kg/dose)
Study: NCT04393441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 011516X (New Artificial Tear Formulation)
Description: Topical eye drops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane Ultra Multidose
Description: Topical eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REFRESH PLUS®
Description: Topical eye drops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REFRESH PLUS®
Description: Topical eye drops
Study: NCT01817179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FES neuroprosthesis to dorsiflexors on affected leg
Study: NCT03332524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP160412 Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg
Description: 2 Ibuprofen and capsules Chlorpheniramine maleate 3 time per day for 72 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2 capsules Ibuprofen and 1 placebo
Description: Ibuprofen and placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: capsule Chlorpheniramine 4mg and 1 Placebo
Description: Chlorpheniramine 4mg and one capsule Placebo 3/72days
Study: NCT01235208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Dr. Fedon Lindbergs Vektcoach Treatment
Description: Diet and lifestyle treatment
Study: NCT01747213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNC

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose fiber
Study: NCT02834780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H3B-6527
Description: H3B-6527 by mouth once or twice daily at specified doses.
Study: NCT03969862

Intervention type: DEVICE
Intervention: NOVEOS® system
Description: The NOVEOS® System is a fully automated, high-throughput immunoassay platform that uses magnetic microbeads as a solid phase.~This is a partially closed system that is primarily intended for the determination of specific IgE with NOVEOS® Hycor allergens. It has the CE mark.

Intervention type: DEVICE
Intervention: NOVEOS® system
Description: The NOVEOS® System is a fully automated, high-throughput immunoassay platform that uses magnetic microbeads as a solid phase.~This is a partially closed system that is primarily intended for the determination of specific IgE with NOVEOS® Hycor allergens. It has the CE mark.
Study: NCT03449030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-164
Description: TAK-164 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-164
Description: TAK-164 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-164
Description: TAK-164 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-TAK-164
Description: 89Zr-TAK-164 intravenous infusion
Study: NCT00062127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02270450

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo abdominal surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo abdominal surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastrointestinal complications management/prevention
Description: Undergo non-surgical management

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastrointestinal complications management/prevention
Description: Undergo non-surgical management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT02912975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tactile treatment
Description: In Tactile Treatment five different sensory stimuli is applied repeatedly to the skin of the affected part of the limb, in the actual case to the amputated limb from ten cm above the knee joint and distally to include the entire amputation stump: gentle touch with a feather, a brush, a piece of paper, a stone and a wooden stick. The stimuli are applied two times daily for five 5 minutes each time, one minute per material.
Study: NCT02363738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation. Infliximab will be prescribed adjunctively to a conventional mood stabilizer or atypical antipsychotic agent.
Study: NCT04019782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagen-PVP
Description: Infiltrations of 1.5 ml collagen-polyvinyl pyrrolidone (collagen-PVP) plus 1 mL of 2% xylocaine without epinephrine, administered by intraarticular injections (three doses, one each 7 days)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hylan G-F 20
Description: Infiltrations of 2 mL 0.8% Hylan G-F 20 (16 mg) solution, administered by intraarticular injections (three doses, one each 7 days)